Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature
- 1 February 2007
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 202-207
- https://doi.org/10.1136/ard.2006.056630
Abstract
To evaluate the feasibility of haematopoietic stem cell transplantation (HSCT) in vasculitis. This is a retrospective analysis of patients who had received HSCT for vasculitic diseases and have been reported to the European League Against Rheumatism autoimmune disease or European Bone Marrow Transplantation ProMISe databases. Information about the disease and outcome was obtained by a questionnaire sent to the referring centres. Response of the disease to HSCT was defined as partial or complete responses according to the ability to reduce immunosuppression after HSCT. In addition, the Medline database was searched for reports on HSCT in patients with vasculitis. Detailed information was obtained for 15 patients, whose median age at HSCT was 37 years. The diagnoses were cryoglobulinaemia in four patients, Behçet's disease in three patients, Wegener's granulomatosis in three patients, and undifferentiated vasculitis, Churg-Strauss angiitis, polychondritis, Takayasu arteritis and polyarteritis nodosa in one patient each. 14 patients received autologous HSCT and 1 an allogeneic HSCT as the first transplant. In three patients, further transplantation was given because of relapse. The overall response, including all consecutive transplantations (HSCT/patient, n = 1-3, median 1.3) to HSCT, was 93%, with 46% complete responses and 46% partial responses; median (range) duration of response at the time of reporting was 45 (16-84) months. Three patients died, one from advanced disease, one from cancer and one from graft-versus-host disease. The Medline search showed five other patients who were effectively treated with HSCT for vasculitic diseases. This retrospective study suggests that autologous HSCT is feasible for vasculitis. Its value remains to be tested in prospective controlled studies.Keywords
This publication has 26 references indexed in Scilit:
- Fever and increasing cANCA titre after kidney and autologous stem cell transplantation for Wegener's granulomatosisAnnals of the Rheumatic Diseases, 2005
- Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Autologous hematopoietic stem cell transplantation for autoimmune diseasesBone Marrow Transplantation, 2005
- Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patientsThe Journal of Experimental Medicine, 2005
- Etanercept plus Standard Therapy for Wegener's GranulomatosisNew England Journal of Medicine, 2005
- Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.2004
- Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohortThe American Journal of Medicine, 1996
- Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases.Annals of the Rheumatic Diseases, 1996
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992